Mandate

Vinge advises AstraZeneca

January 30, 2013

Vinge has advised AstraZeneca in connection with the sale of its research facility in Södertälje to Acturum, a group formed by FAM, the Wallenber foundations’ management company, and PEAB. The transaction covers, among other things, real estate, laboratories, research projects and a significant number of laboratory equipment and is intended to create conditions for future research and enterprise within the entire filed of life science.

Vinge’s team consisted of responsible partner Malin Ohlin and associate Kristina Ekberg and also included partner Patrick Forslund and associates Daniel Unger, Johan Cederblad, Nazli Zia, Peter Alstergren, Claes Henriksson and project assistant Sara Andersson.

Related

Vinge has advised Sertion AB in connection with the acquisition of Svensk Anläggning och Driftteknik AB

Through the acquisition, Sertion takes a further step in its development as a leading international infrastructure and installation group within complex HVAC systems, technical infrastructure, and industrial piping. Svensk Anläggning och Driftteknik AB specializes in certified welding and installation of industrial piping.
February 10, 2026

Vinge has advised Viva Wine Group AB in connection with the acquisition of the Norwegian beverage company Alpha Brands

Vinge has advised Viva Wine Group AB in connection with the acquisition of 60 percent of the shares in the Norwegian beverage company Alpha Brands, for an initial cash purchase price of MNOK 33, with a possible earn-out based on the company's performance development.
February 09, 2026

Vinge advises HAKI Safety AB (publ) in connection with the acquisition of Newbow Aerospace Limited

Newbow Aerospace is a UK-based market-leading manufacturer and supplier of ground support equipment (GSE) used for the safe and efficient maintenance of aircraft.
February 09, 2026